1
|
Effect of Chinese herbal medicine formula on progression-free survival among patients with metastatic colorectal cancer: Study protocol for a multi-center, double-blinded, randomized, placebo-controlled trial. PLoS One 2022; 17:e0275058. [PMID: 36525406 PMCID: PMC9757552 DOI: 10.1371/journal.pone.0275058] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Accepted: 08/23/2022] [Indexed: 12/23/2022] Open
Abstract
INTRODUCTION Metastatic colorectal cancer (mCRC) causes high cancer-related morbidity and mortality worldwide. Although chemotherapy and targeted agents treatment improve median survival and 5-year survival rates, there is only one-third of patients who adhere to treatment protocol until the pause of disease progression. Hezhong granule is a traditional Chinese herbal formula used for mCRC, which has shown good potential in alleviating the adverse effects of chemotherapy, enhancing the effectiveness of chemotherapy, and improving the quality of life. Therefore, the purpose of the study is to further validate the clinical efficacy and safety of the Chinese herbal medicine formula named Hezhong (HZ) in combination with standard chemotherapy and cetuximab (CET) or bevacizumab (BV) for treating mCRC. METHODS In this multi-center, randomized, double-blinded, placebo-controlled trial, 360 eligible mCRC patients who will be randomly assigned to Hezhong or placebo group with a 1: 1 ratio. Participants in the Hezhong group will receive standard chemotherapy and CET or BV plus Hezhong Granule until the pause of disease progression, death, the exhibition of intolerable toxicity, or up to 6 months, while the placebo group will treat with standard chemotherapy and CET or BV plus placebo. The primary endpoint is progression-free survival (PFS). The secondary endpoints are overall survival (OS), objective response rate (ORR), safety, quality of life years (QOL), and chemotherapy-induced nausea and vomiting (CINV). EXPECTED RESULTS The expected results of this trial are to improve the PFS and QOL of patients with mCRC and provide evidence-based recommendations for the treatment of mCRC with traditional Chinese medicine in China. TRIAL REGISTRATION The trial has been registered with the Chinese Clinical Trial Registry (ChiCTR). The trial registration number was ChiCTR2100041643.
Collapse
|
2
|
Zuo Jin Wan Reverses the Resistance of Colorectal Cancer to Oxaliplatin by Regulating the MALAT1/miR-200s/JNK Signaling Pathway. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2022; 2022:3032407. [PMID: 36248422 PMCID: PMC9568309 DOI: 10.1155/2022/3032407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 09/02/2022] [Accepted: 09/10/2022] [Indexed: 11/06/2022]
Abstract
Background Oxaliplatin (L-OHP) is a common chemotherapy drug used in the treatment of colorectal cancer (CRC). Our previous work showed that Zuo Jin Wan (ZJW), a traditional Chinese medicine prescription, could improve sensitivity to L-OHP in the treatment of CRC, but the detailed mechanism is not clear. In previous mechanistic studies, we found that the miR-200s expression in CRC is associated with L-OHP sensitivity through regulation of MDR1/p-gp and the downstream c-JunN-terminal kinase (JNK) signaling pathway. Moreover, lncRNA-MALAT1 offers great potential in the regulation of drug resistance by interacting with miR-200s. Therefore, in this work, we explored whether ZJW could reverse L-OHP resistance in CRC by regulating MALAT1, miR-200s, and the downstream signaling pathway. Methods Cell Counting Kit-8 and flow cytometry were used to detect the effects of ZJW combined with L-OHP on chemotherapy tolerance and cell apoptosis of HCT116/L-OHP cells. Western blotting and quantitative real-time PCR (qRT-PCR) were used to detect the activation of the JNK signaling pathway and the protein and mRNA expression levels of the drug resistance-related MDR1/ABCB1 gene in HCT116/L-OHP cells treated with ZJW. The binding sites of MALAT1 and miR-200s were predicted by bioinformatics tools and confirmed by qRT-PCR. qRT-PCR was used to detect the expression of miR-200s and MALAT1 in HCT116/L-OHP cells treated with ZJW. A xenograft model of CRC in nude mice was established to observe the effect of ZJW combined with L-OHP on the growth of subcutaneously transplanted tumors. Apoptosis in tumor cells was detected by TUNEL staining. The activation of the JNK signaling pathway and the expression of drug resistance-related proteins were detected by immunohistochemistry and immunofluorescence. qRT-PCR was used to detect the expression of miR-200s and the MALAT1 gene in the tumors. Results Our study showed that ZJW could significantly decrease the proliferation and promote apoptosis of HCT116/L-OHP cells treated with L-OHP. We further proved that ZJW could reverse the drug resistance of HCT116/L-OHP cells by reducing MALAT1, indirectly upregulating miR-200s, alleviating the activation of the JNK signaling axis, and downregulating the expression of resistance proteins such as MDR1/ABCB1 and ABCG2. ZJW combined with L-OHP inhibited the growth of subcutaneously transplanted tumors and induced apoptosis in nude mice. ZJW reduced the expression of MALAT1 and upregulated the expression of miR-200s in transplanted tumors. In addition, ZJW also alleviated the activation of the JNK signaling pathway while reducing the expression of MDR1/ABCB1 and ABCG2. Conclusions Our study identified that MALAT1 promotes colorectal cancer resistance to oxaliplatin by reducing the miR-200s expression. ZJW may reverse chemoresistance by inhibiting the expression of MALAT1 and regulating the miR-200s/JNK pathway, providing an experimental basis for the clinical application of ZJW in relieving chemotherapy resistance.
Collapse
|
3
|
Wang Q, Ye H, Wang QQ, Li WT, Yu BB, Bai YM, Xu GH. Chinese Herbal Medicine for Chemotherapy-Induced Leukopenia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. Front Pharmacol 2021; 12:573500. [PMID: 34017246 PMCID: PMC8129503 DOI: 10.3389/fphar.2021.573500] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Accepted: 02/19/2021] [Indexed: 12/24/2022] Open
Abstract
Aim: We conducted a systematic review of high-quality randomized controlled trials (RCTs) to assess the efficacy and safety of Chinese herbal medicine (CHM) for the treatment of chemotherapy-induced leukopenia (CIL). Methods: Eight electronic databases were searched from the date of inception to November 4, 2020 for high-quality RCTs that met the requirements of at least four key domains of the Cochrane risk of bias (RoB) tool. RevMan 5.3 was applied for the meta-analysis. Results: Fourteen RCTs involving 1,053 patients were included. The pooled results showed that CHM + chemotherapy exerted greater beneficial effects on white blood cell (WBC), neutrophil (NEU), hemoglobin (Hb), and platelet (PLT) counts in addition to the Karnofsky performance scale (KPS) score, but showed no significant difference on granulocyte colony-stimulating factor (G-CSF) dosage compared with chemotherapy alone. Placebo (PBO) + chemotherapy and CHM + chemotherapy groups showed no significant differences in terms of reduction of the incidence of neutropenia. CHM + chemotherapy was superior to Western medicine (WM) + chemotherapy in improving the WBC count, KPS, infection amount, G-CSF use rate, and incidence of leukopenia. In addition, no severe adverse events were observed in the 14 RCTs. Conclusion: CHM in combination with chemotherapy could effectively improve the clinical symptoms of CIL when compared with chemotherapy alone or Western medicine + chemotherapy, except when comparing with PBO + chemotherapy. While CHMs were generally safe for clinical use and exerted no severe side effects in the 14 RCTs, high-quality RCTs with larger sample sizes are essential to reduce study heterogeneity.
Collapse
Affiliation(s)
- Qing Wang
- School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China
| | - Hui Ye
- School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China
| | - Qiu-Qin Wang
- School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China.,Public Teaching Department for Foreign Languages, Nanjing University of Chinese Medicine, Nanjing, China
| | - Wei-Tong Li
- School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China
| | - Bei-Bei Yu
- Public Teaching Department for Foreign Languages, Nanjing University of Chinese Medicine, Nanjing, China
| | - Ya-Mei Bai
- School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China
| | - Gui-Hua Xu
- School of Nursing, Nanjing University of Chinese Medicine, Nanjing, China
| |
Collapse
|
4
|
Network pharmacology-based and clinically relevant prediction of active ingredients and potential targets of Chinese herbs on stage IV lung adenocarcinoma patients. J Cancer Res Clin Oncol 2021; 147:2079-2092. [PMID: 33797608 DOI: 10.1007/s00432-020-03488-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Accepted: 11/30/2020] [Indexed: 10/21/2022]
Abstract
AIM This study is designed to ascertain the relative molecular targets of effective Chinese herbs in treating stage IV lung adenocarcinoma based on clinical data and network pharmacology. In addition, we showed that Chinese Herbal Medicine (CHM) treatment was associated with survival benefit for patients with stage IV lung adenocarcinoma and identified 18 herbs beneficial to survival through correlation analysis. BACKGROUND Increasing evidence has shown that CHM has efficient therapeutic effects for advanced lung adenocarcinoma, while active ingredients and potential targets remain unclear. METHODS Kaplan-Meier method and Cox regression analysis were used to evaluate the survival benefit of CHM treatment, and correlation analysis was applied to identify the most effective components in the formulas. A network pharmacological approach was used to decipher the potential therapeutic mechanisms of CHM. RESULTS CHM treatment was an independent protective factor. The hazard ratio (HR) was 0.487 (95% CI 0.293-0.807; P = 0.005). Patients in the CHM group had a longer median survival time (31 months) compared with the non-CHM group (19 months; P < 0.001). 18 out of the total 241 herbs were significantly correlated with favorable survival outcomes (P < 0.05), likely representing the most effective components in these formulas. Bioinformatics analysis suggested that the 18 herbs realize anti-lung-adenocarcinoma activity mainly through (1) inhibiting the activity of some growth factors' receptors, such as HGFR, EGFR, and IGFR. (2) Suppressing angiogenesis not only through VEGFR and PDGFR, but also through the function of neurotransmitters such as dopamine and serotonin. (3) Inhibiting the Ras signaling pathway directly through Ras as well as through ALK and FNTA/FNTB. CONCLUSIONS We performed a network pharmacological method to decipher the underlying mechanisms, which provides a good foundation for herbal research based on clinical data.
Collapse
|
5
|
Chan YT, Cheung F, Zhang C, Fu B, Tan HY, Norimoto H, Wang N, Feng Y. Ancient Chinese Medicine Herbal Formula Huanglian Jiedu Decoction as a Neoadjuvant Treatment of Chemotherapy by Improving Diarrhea and Tumor Response. Front Pharmacol 2020; 11:252. [PMID: 32210825 PMCID: PMC7076183 DOI: 10.3389/fphar.2020.00252] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Accepted: 02/24/2020] [Indexed: 12/25/2022] Open
Abstract
Background Diarrhea is a major gastrointestinal complication in cancer patients receiving chemotherapy. Prognosis and treatment of chemotherapy-induced diarrhea (CID) remain unsatisfactory. This study aims to explore the potential of an ancient Chinese Medicine herbal formula Huanglian Jiedu Decoction (HLJDD) as an adjuvant treatment on CID. Method HLJDD extract was prepared by GMP manufacturing standard with quality and stability being checked. 5-fluorouracil (5-Fu) and irinotecan (CPT-11)-induced diarrhea model in mice was established and pre-, co- and post-treatment of HLJDD was implemented. Mechanism of action was explored by detecting related protein expression. In addition, the effect of HLJDD on diarrhea and tumor response induced by clinical regimens FOLFOX and FOLFIRI was measured in murine orthotopic colorectal cancer model. Results HLJDD exhibited consistency in quality and stability after 24-month storage. Pre-treatment of HLJDD, but not co-treatment or post-treatment, could significantly improve the diarrhea score, body weight loss and intestinal damage in 5-Fu- and CPT-11-treated mice. Pre-treatment of HLJDD reduced cell apoptosis in the intestine of chemotherapy-treated mice, and promoted renewal of intestinal cell wall. CD44 was predicted as the potential target of HLJDD-containing compounds in CID. HLJDD pre-treatment induced presentation of CD44-postive cells in the intestine of chemotherapy-treated mice, and initiated expression of stemness-associated genes. Transcriptional products of the downstream Wnt signaling of CD44 were elevated. Furthermore, pre-treatment of HLJDD could significantly improve the tumor response of clinical chemotherapy regimens FOLFOX and FOLFIRI in orthotopic colorectal cancer, and reduce diarrhea and intestinal damage. Conclusion: Our study suggests the potential of HLJDD as a neoadjuvant treatment of chemotherapy by reducing diarrhea and improving tumor response.
Collapse
Affiliation(s)
- Yau-Tuen Chan
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
| | - Fan Cheung
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
| | - Cheng Zhang
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
| | - Bowen Fu
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
| | - Hor-Yue Tan
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
| | | | - Ning Wang
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
| | - Yibin Feng
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong
| |
Collapse
|
6
|
Ganoderic acid A attenuates lipopolysaccharide-induced lung injury in mice. Biosci Rep 2019; 39:BSR20190301. [PMID: 31072918 PMCID: PMC6533208 DOI: 10.1042/bsr20190301] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2019] [Revised: 04/18/2019] [Accepted: 05/06/2019] [Indexed: 02/06/2023] Open
Abstract
The present study aimed to investigate the protective effects of ganoderic acid A (GAA) on lipopolysaccharide (LPS)-induced acute lung injury. In mouse model of LPS-induced acute lung injury, we found that GAA led to significantly lower lung wet-to-dry weight ratio and lung myeloperoxidase activity, and attenuated pathological damages. In addition, GAA increased superoxide dismutase activity, but decreased malondialdehyde content and proinflammatory cytokines levels in the bronchoalveolar lavage fluid. Mechanistically, GAA reduced the activation of Rho/ROCK/NF-κB pathway to inhibit LPS-induced inflammation. In conclusion, our study suggests that GAA attenuates acute lung injury in mouse model via the inhibition of Rho/ROCK/NF-κB pathway.
Collapse
|
7
|
Danshen Formulae for Cancer: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2019; 2019:2310639. [PMID: 31061667 PMCID: PMC6466905 DOI: 10.1155/2019/2310639] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/24/2018] [Revised: 02/09/2019] [Accepted: 03/04/2019] [Indexed: 02/03/2023]
Abstract
Objective Cancer is one of the most dangerous diseases to human life and there is no radical cure for it. In this paper, we compiled quantities of case history to evaluate the current available evidence of herbal Danshen (Radix Salviae Miltiorrhizae, RSM) formulae for the treatment of cancer by means of the high-quality randomized controlled trials (RCTs). Methods English and Chinese electronic databases were searched from PubMed, the Cochrane Library, EMBASE, and the China National Knowledge Infrastructure (CNKI), VIP database, Wanfang database until September 2018. The methodological quality of the included studies was evaluated by using the method of Cocharne evidence-based medicine system evaluation, the quality was evaluated by screening the literature that met the requirements, and the Review Manager 5.3 was used for statistical analysis. The pooled odds ratio (OR) with 95% CIs was used to estimate the correlation between Danshen formulae and therapeutic effects. Results Thirteen RCTs with 1045 participants were identified. The studies investigated the lung cancer (n = 5), leukemia (n = 3), liver cancer (n = 3), breast or colon cancer (n = 1), and gastric cancer (n = 1). A total of 83 traditional Chinese medicines were used in all prescriptions and there were 3 different dosage forms. Meta-analysis suggested that Danshen formulae had a significant effect on RR (response rate) (OR 2.38, 95% CI 1.66-3.42), 1-year survival (OR 1.70 95% CI 1.22-2.36), 3-year survival (OR 2.78, 95% CI 1.62-4.78), and 5-year survival (OR 8.45, 95% CI 2.53-28.27). Conclusion The current research results showed that Danshen formulae combined with chemotherapy for cancer treatment was better than conventional drug treatment plan alone.
Collapse
|
8
|
Liew AC, Peh KK, Tan BS, Zhao W, Tangiisuran B. Evaluation of chemotherapy-induced toxicity and health-related quality of life amongst early-stage breast cancer patients receiving Chinese herbal medicine in Malaysia. Support Care Cancer 2019; 27:4515-4524. [PMID: 30911917 DOI: 10.1007/s00520-019-04724-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Accepted: 03/01/2019] [Indexed: 11/12/2022]
Abstract
PURPOSE This observational study aimed to compare the outcome and health-related quality of life (HRQOL) amongst breast cancer patients using Chinese herbal medicine (CHM) and those not using CHM during chemotherapy. METHODS A prospective, non-randomised longitudinal study was conducted in two government integrated hospitals over an 8-month period. Early-stage breast cancer patients who were (1) either already using complementary and alternative medicine (CAM) or not and (2) who were on a regime of 5-fluorouracil, epirubicin, and cyclophosphamide were included in the study. Patients who agreed to receive CHM were assigned to receive individualised CHM prescriptions deemed suitable for the individual at a particular time. Those who were not willing to take Chinese herbal medicines (CHM) were assigned to the non-CHM control group. Blood profile and chemotherapy-induced AE were recorded whilst HRQOL assessment was done using the EORTC QLQ-C30 questionnaire on first, third, and sixth cycles. RESULTS Forty-seven patients [32 female vs. 1 male, p = 0.31; mean year of age: 52.2(SD = 7.6), p = 0.28)}] were recruited during the study period. Demographics of both groups were comparable. Fifty percent of respondents reported using some kind of CAM before chemotherapy. Diet supplements (40.6%) were the most common CAM used by the respondents. The study showed that patients using CHM had significantly less fatigue (p = 0.012), nausea (p = 0.04), and anorexia (p = 0.005) during chemotherapy. There were no significant differences in patients' HRQOL (p = 0.79). There were no AEs reported during the study. CONCLUSION The use of CHM as an adjunct treatment with conventional chemotherapy have been shown to reduce fatigue, nausea, and anorexia in breast cancer patients but did not reduce chemotherapy-associated hematologic toxicity. The sample size of this study was not powered to assess the significance of HRQOL between two groups of patients.
Collapse
Affiliation(s)
- Ai Ch'i Liew
- Clinical Research Centre, Hospital Seberang Jaya, Jalan Tun Hussein Oon, 13700, Perai, Penang, Malaysia.
| | - Kok-Khiang Peh
- School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800, Gelugor, Penang, Malaysia
| | - Boon Seang Tan
- Department of Clinical Oncology and Radiotherapy, Penang General Hospital, Jalan Residensi, 10990, George Town, Penang, Malaysia
| | - Wei Zhao
- Traditional Chinese Medicine Oncology Physician, Guang'anmen Hospital (of Traditional Chinese Medicine), Beijing, No. 5, Bei Xian Ge, Xuan Wu District, Beijing, 100053, China
| | | |
Collapse
|
9
|
Feng D, Tang T, Fan R, Luo J, Cui H, Wang Y, Gan P. Gancao (Glycyrrhizae Radix) provides the main contribution to Shaoyao-Gancao decoction on enhancements of CYP3A4 and MDR1 expression via pregnane X receptor pathway in vitro. Altern Ther Health Med 2018; 18:345. [PMID: 30594244 PMCID: PMC6311034 DOI: 10.1186/s12906-018-2402-7] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Accepted: 12/06/2018] [Indexed: 01/11/2023]
Abstract
BACKGROUND Chinese herbal formula Shaoyao Gancao decoction (SGD) is often used as an adjuvant with chemotherapeutic agents to treat cancer. Due to the herb-drug interactions, the alternations of drug metabolic enzyme and drug transporters induced by SGD deserve to be explored. We aimed to investigate the effect of SGD on the pregnane X receptor (PXR)-mediated transcriptional regulation of cytochrome P450 3A4 (CYP3A4) and drug transporter multidrug resistance protein 1 (MDR1) in vitro. Besides, we assessed the contribution of constituent herbs to SGD on the regulation of CYP3A4 and MDR1. METHODS The dual luciferase reporter gene system containing the hPXR expression plasmid and the reporter gene plasmid of CYP3A4 or MDR1 was co-transfected to HepG2 and Caco2 cells. Luciferase activities were determined using a Dual-luciferase reporter assay kit. The gene expression of CYP3A4 and MDR1 in the hPXR-transfected LS174T cells were assessed by real-time qPCR. Finally, the contribution of constituent herbs from SGD was evaluated. RESULTS SGD, Shaoyao and Gancao concentration-dependently increased promoter activities of CYP3A4 and MDR1 in vitro. Moreover, SGD, Shaoyao and Gancao up-regulated CYP3A4 and MDR1 mRNA in hPXR-transfected LS174T cells. As the herbal constituent of SGD, Gancao possesses significantly higher levels of metabolic enzyme and drug transporters compared with Shaoyao. CONCLUSION SGD tends to enhance CYP3A4 and MDR1 expression via PXR pathway, especially Gancao provides the main contribution. This study highlights a potential in vitro mechanism for SGD on the regulation of drug metabolic enzymes and drug transporters.
Collapse
|
10
|
Kasymjanova G, Tran AT, Cohen V, Pepe C, Sakr L, Small D, Agulnik JS, Jagoe RT. The use of a standardized Chinese herbal formula in patients with advanced lung cancer: a feasibility study. JOURNAL OF INTEGRATIVE MEDICINE-JIM 2018; 16:390-395. [PMID: 30292672 DOI: 10.1016/j.joim.2018.09.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Accepted: 07/05/2018] [Indexed: 10/28/2022]
Abstract
OBJECTIVE Increasing numbers of cancer patients are using Chinese herbs (CHs). However, differences among prior studies make it difficult to draw firm conclusions about the clinical usefulness of any specific CH formula. The primary objective of this study was to establish the acceptability of taking a standardized CH formula for patients with advanced lung cancer. The secondary objective was to identify any toxicities attributable to this CH formula and to measure changes in quality of life. METHODS A single-arm, prospective study of a 6-week intervention with a selected CH formula in 15 patients with stage 4 nonsmall-cell lung cancer (NSCLC, Seventh American Joint Committee on Cancer TNM staging system). RESULTS Patients with advanced lung cancer were interested in using the CH formula. Completion (93%) and adherence (98%) levels were very high and most patients perceived the CH treatment as easy to take and were willing to take the CHs used in the study again if it was available. About half of the patients reported adverse events, all of which were mild (Grade 1 or 2) and only a small minority (8%) were potentially related to CHs. No biochemical or hematological evidence of toxicity was observed. Overall, there were improvement in quality of life, and reduced feelings of tiredness and sleepiness. CONCLUSION This study provides preliminary evidence that short-term use of a carefully selected and prepared CH formula in patients with stage 4 NSCLC is acceptable and safe.
Collapse
Affiliation(s)
- Goulnar Kasymjanova
- Peter Brojde Lung Cancer Center, Segal Cancer Center, Jewish General Hospital, Montreal H3T 1E2, Canada.
| | - Anh-Thi Tran
- Peter Brojde Lung Cancer Center, Segal Cancer Center, Jewish General Hospital, Montreal H3T 1E2, Canada
| | - Victor Cohen
- Peter Brojde Lung Cancer Center, Segal Cancer Center, Jewish General Hospital, Montreal H3T 1E2, Canada
| | - Carmela Pepe
- Peter Brojde Lung Cancer Center, Segal Cancer Center, Jewish General Hospital, Montreal H3T 1E2, Canada
| | - Lama Sakr
- Peter Brojde Lung Cancer Center, Segal Cancer Center, Jewish General Hospital, Montreal H3T 1E2, Canada
| | - David Small
- Peter Brojde Lung Cancer Center, Segal Cancer Center, Jewish General Hospital, Montreal H3T 1E2, Canada
| | - Jason Scott Agulnik
- Peter Brojde Lung Cancer Center, Segal Cancer Center, Jewish General Hospital, Montreal H3T 1E2, Canada
| | - Robert Thomas Jagoe
- Peter Brojde Lung Cancer Center, Segal Cancer Center, Jewish General Hospital, Montreal H3T 1E2, Canada
| |
Collapse
|
11
|
Use of Chinese Herbal Medicine Improves Chemotherapy-Induced Thrombocytopenia among Gynecological Cancer Patients: An Observational Study. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2018; 2018:4201325. [PMID: 30174705 PMCID: PMC6106719 DOI: 10.1155/2018/4201325] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Revised: 06/04/2018] [Accepted: 06/10/2018] [Indexed: 11/18/2022]
Abstract
Background Chemotherapy-induced thrombocytopenia (CIT) is a serious complication among patients with gynecological malignancies, yet management options are limited. This study aimed at reporting the potential of the Chang Gung platelet elevating formula (CGPEF), a prescription with a fixed proportion of Chinese herbs, for improving CIT among gynecologic cancer patients. Materials From 1/1/2007 to 31/12/2009, a total of 23 patients with two consecutive CIT episodes (≤ 100×103 /μL) (last cycle: C0; index cycle: C1) received the CGPEF from the nadir of platelet count of C1 and through the subsequent chemotherapy cycles (C2 and beyond). The CGPEF was taken orally four times a day. The evolution of platelet counts of 18 patients after administration of CGPEF was analyzed (2 patients had different chemotherapy regimens after CGPEF, two patients discontinued CGPEF due to the flavor and the amount of CGPEF, and one patient had no further chemotherapy). Results Most of the patients had recurrent ovarian cancer (11/18, 61%) with a median of 2.5 previous chemotherapy regimens, and carboplatin-based regimens were the most commonly used for these patients (13/18, 72%). The trend of successive CIT could be reversed after taking CGPEF. Also, the platelet nadir was higher after CGPEF treatment (16.5×103/μL versus 32×103/μL, before and after CGPEF treatment, resp., p = 0.002). Moreover, the chemotherapy interval decreased from 30.5 days to 24 days. No thrombocytosis, clinical bleeding, thromboembolism, or other adverse events were found among these patients. Conclusions The CGPEF is worthy of further large-scale, well-designed clinical trials for CIT among gynecological cancer patients.
Collapse
|
12
|
Xu Y, Mao JJ, Sun L, Yang L, Li J, Hao Y, Li H, Hou W, Chu Y, Bai Y, Jia X, Wang J, Shen L, Zhang Y, Wang J, Liu J, Yang Y. Association Between Use of Traditional Chinese Medicine Herbal Therapy and Survival Outcomes in Patients With Stage II and III Colorectal Cancer: A Multicenter Prospective Cohort Study. J Natl Cancer Inst Monogr 2018; 2017:4617830. [PMID: 29140496 DOI: 10.1093/jncimonographs/lgx015] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Accepted: 08/16/2017] [Indexed: 12/28/2022] Open
Abstract
Background Chinese cancer patients often use Traditional Chinese Medicine (TCM) herbal medicine during or after active cancer treatments. However, little is known about how TCM herbal medicine impacts cancer outcomes. This study aimed to evaluate the association between TCM herbal therapy and survival outcomes in patients with stage II or III colorectal cancer. Methods We conducted an eight-center prospective cohort study in China among patients who had undergone radical resection for stage II and III colorectal cancer. All patients received comprehensive conventional treatments according to National Comprehensive Cancer Network (NCCN) guidelines, and follow-up visits were conducted over five years. We defined high exposure as a patient's use of TCM individualized herbs for more than one year, ascertained via clinical interviews. The primary outcome was disease-free survival (DFS), with overall survival (OS) as a secondary outcome. Results Between April 2007 and February 2009, we enrolled 312 patients into the cohort; 166 (53.2%) met the definition of high exposure to TCM herbs. Adjusting for covariates, high exposure to TCM was associated with both better DFS (hazard ratio [HR] = 0.62, 95% confidence interval [CI] = 0.39 to 0.98) and OS (HR = 0.31, 95% CI = 0.14 to 0.68). In subgroup exploratory analysis, the effects demonstrated that the differences in outcomes were statistically significant in patients who had received chemotherapy. Conclusion Longer duration of TCM herbal use is associated with improved survival outcomes in stage II and III colorectal cancer patients in China. More research is needed to evaluate the effects and underlying mechanisms of herbal medicine on colorectal cancer outcomes.
Collapse
Affiliation(s)
- Yun Xu
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Jun J Mao
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Lingyun Sun
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Lin Yang
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Jie Li
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Yingxu Hao
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Huashan Li
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Wei Hou
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Yuping Chu
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Yu Bai
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Xiaoqiang Jia
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Jinwan Wang
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Lin Shen
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Ying Zhang
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Jianbin Wang
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Jianping Liu
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| | - Yufei Yang
- Oncology Department, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Integrative Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Internal Oncology Department, Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China; Gastroenterology Department, Peking University of Cancer Hospital and Beijing Cancer Hospital, Beijing, China; Integrative Traditional Chinese Medicine and Western Medicine Department, China-Japan Friendship Hospital, Beijing, China; Oncology Department, Guanganmen Hospital of China Academy of Chinese Medical Sciences, Beijing, China; Oncology Department, Beijing Chaoyang Hospital of Capital Medical University, Beijing China; Gastroenterology Department, No. 1 Hospital of Peking University, Beijing, China; Epidemiology Department, Beijing University of Chinese Medicine, Beijing, China
| |
Collapse
|
13
|
Association of herbal/botanic supplement use with quality of life, recurrence, and survival in newly diagnosed stage II colon cancer patients: A 2-y follow-up study. Nutrition 2018; 54:1-6. [PMID: 29674230 DOI: 10.1016/j.nut.2018.02.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2017] [Revised: 01/11/2018] [Accepted: 02/03/2018] [Indexed: 12/14/2022]
Abstract
OBJECTIVES Our objective was to investigate the association between herbal/botanic supplement use and perceived quality of life (QoL), cancer recurrence, and all-cause mortality in colon cancer patients. METHODS Patients (n = 453) newly diagnosed with stage II adenocarcinoma of the colon between 2009 and 2011 were recruited from the North Carolina Central Cancer Registry. Data including demographic variables, herbal medicine use and frequency, lifestyle, diet, cancer treatment, and QoL were collected by interviews at diagnosis (baseline) and 1 and 2 y after diagnosis. Mortality information was obtained via the National Death Index. The Functional Assessment of Cancer Therapy-Colorectal (FACT-C) and Medical Outcomes Short Form 12 (SF-12) were used to evaluate QoL. RESULTS At baseline, herbal/botanic supplement users were more likely to have a healthier lifestyle than non-users, including more physical activity (P <0.01), more fruit and vegetable consumption (P = 0.01), less smoking (P <0.01), and less energy intake from fat (P = 0.02). After adjustment for potential confounders, no significant association was found between herbal/botanic supplement use and QoL assessed by FACT-C and SF-12. Similarly, herbal/botanic supplement use was not associated with the risk of recurrence, all-cause mortality or the combined. CONCLUSION In this study, patients with stage II colon cancer using herbal/botanic supplements had no significant improvement in their QoL and no difference in odds of colon cancer recurrence and all-cause mortality over 2 y after diagnosis compared with those who did not use herbs/botanicals. Further studies are warranted to confirm the findings and to focus on types of herbal/botanic supplements.
Collapse
|
14
|
Oral Chinese Herbal Medicine as an Adjuvant Treatment for Chemotherapy, or Radiotherapy, Induced Myelosuppression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2017; 2017:3432750. [PMID: 28855947 PMCID: PMC5569637 DOI: 10.1155/2017/3432750] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Revised: 02/08/2017] [Accepted: 03/07/2017] [Indexed: 11/25/2022]
Abstract
Objective Myelosuppression is a common side effect in cancer patients receiving chemotherapy or radiotherapy. Chinese herbal medicine (CHM) has shown promise in alleviating myelosuppression. Method We searched for randomized controlled trials (RCTs) from seven databases without language restriction. We included RCTs in adults, in which hematological toxicity was measured according to WHO criteria and control group underwent chemotherapy and/or radiotherapy and the treatment group was given oral CHM. Results We searched 1021 articles from the date of databases inception to October 7, 2016. We selected 14 articles for the final analysis. Pooled data showed that CHM significantly decreased the suppression rate of leukocytes, neutrophils, hemoglobin, and platelets compared with the control group, particularly in grade III-IV toxicity (leukocytes: RR = 0.43, 95% CI = 0.33–0.56; neutrophils: RR = 0.39, 95% CI = 0.27–0.58; hemoglobin: RR = 0.33, 95% CI = 0.18–0.61; platelets: RR = 0.61, 95% CI = 0.39–0.95). Conclusions CHM as an adjuvant can alleviate myelosuppression induced by chemotherapy or radiotherapy, reduce grade III-IV toxicity, and maintain therapeutic dose and treatment cycle. However, due to heterogeneity and publication bias, the results should be interpreted with caution and validated by conducting strictly designed multicenter RCTs of high quality and large scale.
Collapse
|
15
|
Liang J, Liang J, Hao H, Lin H, Wang P, Wu Y, Jiang X, Fu C, Li Q, Ding P, Liu H, Xiong Q, Lai X, Zhou L, Chan S, Hou S. The Extracts of Morinda officinalis and Its Hairy Roots Attenuate Dextran Sodium Sulfate-Induced Chronic Ulcerative Colitis in Mice by Regulating Inflammation and Lymphocyte Apoptosis. Front Immunol 2017; 8:905. [PMID: 28824631 PMCID: PMC5539173 DOI: 10.3389/fimmu.2017.00905] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2017] [Accepted: 07/14/2017] [Indexed: 01/24/2023] Open
Abstract
Morinda officinalis is beneficial for the treatment of inflammatory bowel disease (IBD). The hairy root with higher genetic and biochemical stability cultured from M. officinalis might have similar effects to treat IBD. In this study, the main chemical composition of the root extracts of M. officinalis (MORE) native plant and the hairy root extract of M. officinalis (MOHRE) was compared by quantitative HPLC. The difference of their therapeutic effects and potential mechanism was evaluated using 3% dextran sodium sulfate-induced chronic colitis in mice and T lymphocytes in vitro. The results found that MOHRE possesses many specific peaks unobserved in the chromatogram of native plant. The content of iridoids in the MORE (3.10%) and MOHRE (3.01%) is somewhat similar but quite different for their anthraquinones’s content (0.14 and 0.66%, respectively). Despite all this, treatment with both MORE and MOHRE significantly attenuated the symptoms of colitis, including diarrhea, body weight loss, colon shortening, histological damage, and decreased inflammatory cytokine levels. In addition, they dose-dependently increased the apoptosis of T lymphocyte in vivo and in vitro. And, the differences for treatment effects on ulcerative colitis (UC) between them both in this study were mostly insignificant. The results demonstrated that the effects of MORE and MOHRE for the treatment of UC are similar, although there are a few difference on their chemical composition, indicating the hairy root cultured from M. officinalis might be able to replace its native plant on treatment of UC. The successful derivation of a sustainable hairy root culture provides a model system to study the synthetic pathways for bioactive metabolites, which will make the use of bioreactors to largely produce traditional medicine become reality.
Collapse
Affiliation(s)
- Jian Liang
- Guangdong Provincial Key Laboratory of New Chinese Medicinals Development and Research, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Jiwang Liang
- Shenzhen Fan Mao Pharmaceutical Co., Limited, Shenzhen, China
| | - Hairong Hao
- Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China
| | - Huan Lin
- Guangdong Provincial Key Laboratory of New Chinese Medicinals Development and Research, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Peng Wang
- Shenzhen Fan Mao Pharmaceutical Co., Limited, Shenzhen, China
| | - Yanfang Wu
- Guangdong Provincial Key Laboratory of New Chinese Medicinals Development and Research, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Xiaoli Jiang
- Shenzhen Fan Mao Pharmaceutical Co., Limited, Shenzhen, China
| | - Chaodi Fu
- Shenzhen Fan Mao Pharmaceutical Co., Limited, Shenzhen, China
| | - Qian Li
- Guangdong Provincial Key Laboratory of New Chinese Medicinals Development and Research, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Ping Ding
- Guangdong Provincial Key Laboratory of New Chinese Medicinals Development and Research, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Huazhen Liu
- Section of Immunology, Guangdong Provincial Academy of Chinese Medical Sciences, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
| | - Qingping Xiong
- Guangdong Provincial Key Laboratory of New Chinese Medicinals Development and Research, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Xiaoping Lai
- Guangdong Provincial Key Laboratory of New Chinese Medicinals Development and Research, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Lian Zhou
- Guangdong Provincial Key Laboratory of New Chinese Medicinals Development and Research, Guangzhou University of Chinese Medicine, Guangzhou, China
| | - Shamyuen Chan
- Shenzhen Fan Mao Pharmaceutical Co., Limited, Shenzhen, China
| | - Shaozhen Hou
- Guangdong Provincial Key Laboratory of New Chinese Medicinals Development and Research, Guangzhou University of Chinese Medicine, Guangzhou, China
| |
Collapse
|
16
|
Wang X, Sun D, Tai J, Wang L. Ganoderic acid A inhibits proliferation and invasion, and promotes apoptosis in human hepatocellular carcinoma cells. Mol Med Rep 2017; 16:3894-3900. [PMID: 28731159 PMCID: PMC5646967 DOI: 10.3892/mmr.2017.7048] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Accepted: 02/14/2017] [Indexed: 12/23/2022] Open
Abstract
Ganoderic acid A (GA-A), a triterpenoid, has been demonstrated to suppress cell proliferation in various cancers, including breast cancer and osteosarcoma. However, its effect on human hepatocellular carcinoma (HCC) remains to be elucidated. The present study aimed to investigate the effect of GA-A on HCC cells in vitro. The HepG2 and SMMC7721 human HCC cell lines were treated with differing concentrations of GA-A for 24, 48 and 72 h. The cell growth rate, cell cycle and apoptosis, migration and invasion were determined using a Cell Counting Kit-8, flow cytometry and transwell assays, respectively. The expression of apoptosis-associated proteins was detected via western blot analysis. GA-A significantly inhibited the proliferation of human HCC HepG2 and SMMC7721 cells in a dose-dependent manner. Furthermore, GA-A induced cell cycle arrest at the G0/G1 phase and apoptosis, and suppressed the migration and invasion of HCC cells. Furthermore, GA-A decreased the expression of cyclin D1 and increased the expression of p21 and cleaved caspase-3. In conclusion, GA-A suppressed the proliferation of human HCC cells in vitro and may act as a promising natural therapeutic reagent in the treatment of HCC.
Collapse
Affiliation(s)
- Xu Wang
- Department of Colorectal and Anal Surgery, The First Hospital, Jilin University, Changchun, Jilin 130000, P.R. China
| | - Di Sun
- Department of Colorectal and Anal Surgery, The First Hospital, Jilin University, Changchun, Jilin 130000, P.R. China
| | - Jiandong Tai
- Department of Colorectal and Anal Surgery, The First Hospital, Jilin University, Changchun, Jilin 130000, P.R. China
| | - Lei Wang
- Department of Colorectal and Anal Surgery, The First Hospital, Jilin University, Changchun, Jilin 130000, P.R. China
| |
Collapse
|
17
|
Ting CT, Kuo CJ, Hu HY, Lee YL, Tsai TH. Prescription frequency and patterns of Chinese herbal medicine for liver cancer patients in Taiwan: a cross-sectional analysis of the National Health Insurance Research Database. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE 2017; 17:118. [PMID: 28219357 PMCID: PMC5319102 DOI: 10.1186/s12906-017-1628-0] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/15/2016] [Accepted: 02/08/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Chinese herbal medicine (CHM) is frequently provided to HCC patients. The aim of this study was to understand the prescription frequency and patterns of CHM for HCC patients by analyzing the claims data from the National Health Insurance (NHI) in Taiwan. METHODS We identified 73918 newly diagnosed HCC subjects from the database of Registry for Catastrophic Illness during 2002 to 2009 and to analyze the frequency and pattern of corresponding CHM prescriptions for HCC patients. RESULTS There were a total of 685,079 single Chinese herbal prescriptions and 553,952 Chinese herbal formula prescriptions used for 17,373 HCC subjects before 2 years of HCC diagnosis. Among the 13,093 HCC subjects who used CHMs after HCC diagnosis, there were 462,786 single Chinese herbal prescriptions and 300,153 Chinese herbal formula prescriptions were counted. By adjusting with person-year and ratio of standardized incidence rate, the top ten prescribed single herbal drugs and Chinese herbal formulas for HCC patients were described in our study. Among them, we concluded that, Oldenlandia diffusa (Chinese herbal name: Bai-Hua-She-She-Cao), Radix et Rhizoma Rhei (Da Huang) and the herbal preparation of Xiao-Chai-Hu-Tang and Gan-Lu-Yin, were the most obviously increased and important CHMs been used for HCC patients. CONCLUSION We established an accurate and validated method for the actual frequency and patterns of CHM use in treating HCC in Taiwan. We propose that these breakthrough findings may have important implications for HCC therapy, clinical trials and modernization of CHM.
Collapse
Affiliation(s)
- Chin-Tsung Ting
- Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, 155, Li-Nong Street, Section 2, Taipei, 112, Taiwan
- Division of Gastrointestinal Surgery, Department of Surgery, Ren-Ai Branch, Taipei City Hospital, Taipei, Taiwan
| | - Chian-Jue Kuo
- Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan
- Department of Psychiatry, School of Medicine, Taipei Medical University and Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan
| | - Hsiao-Yun Hu
- Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan
- Department of Chemical Engineering, National United University, Miaoli, Taiwan
| | - Ya-Ling Lee
- Institute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan.
- Department of Dentistry, Heping Fuyou Branch, Taipei City Hospital, No. 33 Zhonghua Rd., Sec. 2, Taipei, 100, Taiwan.
- Department of Dentistry, School of Dentistry, National Yang-Ming University, Taipei, Taiwan.
| | - Tung-Hu Tsai
- Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, 155, Li-Nong Street, Section 2, Taipei, 112, Taiwan.
- Department of Chemical Engineering, National United University, Miaoli, Taiwan.
| |
Collapse
|
18
|
Cohen Z, Maimon Y, Samuels N, Berger R. Role of reactive oxygen species in the anticancer activity of botanicals: Comparing sensitivity profiles. Oncol Lett 2017; 13:2642-2648. [PMID: 28454445 PMCID: PMC5403330 DOI: 10.3892/ol.2017.5747] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Accepted: 06/27/2016] [Indexed: 11/05/2022] Open
Abstract
Numerous botanicals have been shown to exhibit in vitro and in vivo anticancer activity, some of which is the result of the induction of reactive oxygen species (ROS) in cancer cells with a high ROS content. The present study compared sensitivities to a series of botanicals among cancer cell lines, using an XTT viability test, in order to create a specific cancer-herb profile. Of the 27 botanicals screened, 10 exhibited a cytotoxic effect, 7 of which were ROS-mediated. The sensitivity profiles of the ROS-inducing botanicals in 10 cancer cell lines were similar, unlike 3 cytotoxic ROS-independent botanicals that displayed divergent botanical-specific profiles. The correlation between sensitivity profiles of ROS-inducing botanicals suggests a common mechanism of action, in contrast to the varied mechanism of ROS-independent botanicals. This implies that the investigation of the anticancer activity of botanicals should start with the examination of ROS-mediated activity. Further investigation of ROS sensitivity among various tumor types is required in order to guide research into developing evidence-based guidelines in the use of botanicals for cancer treatment.
Collapse
Affiliation(s)
- Zoya Cohen
- Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, 52621 Ramat Gan, Israel
| | - Yair Maimon
- Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, 52621 Ramat Gan, Israel
| | - Noah Samuels
- Tal Center for Integrative Oncology, Institute of Oncology, Sheba Medical Center, 52621 Ramat Gan, Israel
| | - Raanan Berger
- Institute of Oncology, Sheba Medical Center, 52621 Ramat Gan, Israel
| |
Collapse
|
19
|
McCulloch M, Ly H, Broffman M, See C, Clemons J, Chang R. Chinese Herbal Medicine and Fluorouracil-Based Chemotherapy for Colorectal Cancer: A Quality-Adjusted Meta-Analysis of Randomized Controlled Trials. Integr Cancer Ther 2016; 15:285-307. [PMID: 27151587 PMCID: PMC5739191 DOI: 10.1177/1534735416638738] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 01/12/2016] [Accepted: 01/25/2016] [Indexed: 12/13/2022] Open
Abstract
Background Chinese herbal medicines reportedly increase efficacy and minimize toxicity of chemotherapy; however, little attention has been paid to how poor study quality can bias outcomes. Methods We systematically searched MEDLINE, TCMLARS, EMBASE, and Cochrane Library for randomized controlled trials of Chinese herbal medicines combined with fluorouracil-based chemotherapy compared with the same chemotherapy alone. We screened for eligibility, extracted data, and pooled data with random-effects meta-analysis. Outcome measures were survival, toxicity, tumor response, performance status, quality of life, and Cochrane Risk of Bias (ROB) criteria to critically evaluate the quality of reporting in the randomized trials included in the meta-analysis. Results We found 36 potentially eligible studies, with only 3 (those with low ROB) qualifying for meta-analysis. Two reported chemotherapy-related diarrhea reduced by 57% (relative risk [RR] = 0.43; 95% CI = 0.19-1.01; I(2) test for variation in RR due to heterogeneity = 0.0%), with nonsignificant results. Two reported white blood cell toxicity reduced by 66% (RR = 0.34; 95% CI = 0.16-0.72; I(2) test for variation in RR due to heterogeneity = 0.0%), with statistically significant results. Stratifying analysis by studies with high versus low ROB, we found substantial overestimation of benefit: Studies with high ROB overestimated by nearly 2-fold reduction of platelet toxicity by Chinese herbal medicines (RR = 0.35, 95% CI = 0.15-0.84 vs RR = 0.65, 95% CI = 0.11-3.92). Studies with high ROB overestimated by nearly 2-fold reduction of vomiting toxicity (RR = 0.45, 95% CI = 0.33-0.61 vs RR = 0.87, 95% CI = 0.48-1.58). And, studies with high ROB overestimated by 21% the reduction in diarrhea toxicity (RR = 0.34, 95% CI = 0.20-0.58 vs RR = 0.43, 95% CI = 0.19-1.01). Studies with high ROB also overestimated by 16% improvement in tumor response (RR = 1.39, 95% CI = 1.18-1.63 vs RR = 1.20; 95% CI = 0.81-1.79). Not accounting for ROB would have exaggerated evidence of benefit and failed to detect nonsignificance of results. Conclusions In the present analysis, involving 36 studies, 2593 patients, 20 outcomes, 36 medical institutions, and 271 named research authors, 92% of the data points were from studies at high ROB. Given the poor quality of the data in studies identified, it cannot be concluded whether combining Chinese herbs with chemotherapy reduces toxicity of chemotherapy.
Collapse
Affiliation(s)
| | - Helen Ly
- Pine Street Foundation, San Anselmo, CA, USA
| | | | - Caylie See
- Pine Street Foundation, San Anselmo, CA, USA
| | - Jen Clemons
- Pine Street Foundation, San Anselmo, CA, USA
| | | |
Collapse
|
20
|
Hung HY, Tseng YH, Liao CM, Chen SY, Wu TP, Lee YC, Chen YM. The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment. Integr Cancer Ther 2016; 16:126-131. [PMID: 27151582 PMCID: PMC5736065 DOI: 10.1177/1534735416645181] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Background. Chinese herbal medicine (CHM) has been used for thousands of year in Eastern countries. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard treatment in stage IV pulmonary adenocarcinoma patients who had tumor EGFR mutations. This study was to find the efficacy of CHM on lung cancer treatment. Materials and Methods. We retrospectively reviewed chart records of our stage IV EGFR-mutated pulmonary adenocarcinoma patients who received first-line EGFR-TKI treatment from January 2010 to September 2014. Results. Total, 527 patients were studied. Among them, 34 patients received CHM treatment, including 24 patients who received CHM treatment from the beginning of first-line EGFR-TKI treatment and 10 patients who started to receive CHM treatment after their disease had progressed to EGFR-TKI treatment. Median progression-free survival (PFS) of first-line EGFR-TKI treatment was numerically better in patients who also received CHM than those who did not (12.1 months vs 10.5 months, P = .7668). Overall survival of those 24 patient who received CHM treatment together with EGFR-TKI was 30.63 months (95% CI = 11.7 to not reached), compared to 23.67 months in the remaining patients (95% CI = 21.37-26; hazard ratio = 0.75; P = .399). No increase of CHM-related toxicities was found during CHM treatment, compared with EGFR-TKI treatment alone (P > .05). Conclusion. Alternative CHM treatment during first-line EGFR-TKI treatment did no harm to the patients and PFS and overall survival was numerically better, although not significant, than those patients who did not receive CHM treatment.
Collapse
Affiliation(s)
- Hsiu-Ying Hung
- 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China
| | - Yen-Han Tseng
- 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.,2 National Yang-Ming University, Taipei, Taiwan, Republic of China
| | - Chia-Miao Liao
- 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China
| | - Sung-Yi Chen
- 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China
| | - Ta-Peng Wu
- 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China
| | - Yu-Chin Lee
- 3 Sijhih Cathay General Hospital, Taipei, Taiwan, Republic of China
| | - Yuh-Min Chen
- 1 Taipei Veterans General Hospital, Taipei, Taiwan, Republic of China.,2 National Yang-Ming University, Taipei, Taiwan, Republic of China.,4 Taipei Medical University, Taipei, Taiwan, Republic of China
| |
Collapse
|
21
|
Shi Q, Li W, Le QQ, Chen WT, Ren JL, Li Q, Hou FG. Attenuated effects of Jianpi Qushi herbs on patients receiving FOLFOX4 after colorectal cancer surgery: A meta-analysis. Chin J Integr Med 2016:10.1007/s11655-015-2437-2. [PMID: 26779712 DOI: 10.1007/s11655-015-2437-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2014] [Indexed: 02/07/2023]
Abstract
OBJECTIVE To systematically review the attenuating effects of invigorating Pi (Spleen) and eliminating dampness (Jianpi Qushi, JPQS) herbs on post-operational colorectal cancer patients receiving FOLFOX4 [5-fluorouracil (5-FU) + folinic acid + oxaliplatin] treatment. METHODS China National Knowledge Infrastructure, Wanfang Data, China Science and Technology Journal Database, PubMed/MEDLINE, EMBASE, and the Cochrane Library databases (up to May 2014) were searched in English or Chinese, and clinical trials with specifific inclusion criteria were collected. Data were analyzed by using Stata 12. RESULTS The meta-analysis comprised 8 randomized clinical studies of 449 patients (238 in the treatment group and 211 in the control group). The results showed that JPQS herbs could improve the quality of life for post-operational colorectal cancer patients receiving FOLFOX4 [weighted mean difference (WMD) = 8.883, 95% confifidence interval (CI): 5.548 to 12.217]; alleviate the symptoms defifined by Chinese medicine [odds ratio (OR) = 5.741, 95% CI: 3.683 to 8.947]; and reduce the incidence rate of neutropenia [relative risk (RR) = 0.669, 95% CI: 0.503 to 0.888], decreased hemoglobin (RR = 0.654, 95% CI: 0.464 to 0.922), diarrhea (RR = 0.427, 95% CI: 0.275 to 0.662), nausea and vomiting (RR = 0.502, 95% CI: 0.390 to 0.648), and neurotoxic reactions (RR = 0.752, 95% CI: 0.595 to 0.951); however, the results showed no signifificant difference in the incidence rate of thrombocytopenia or liver and kidney dysfunction. CONCLUSION JPQS herbs can improve the quality of life for patients undergoing FOLFOX4 treatment after colorectal cancer surgery, relieve symptoms, and somewhat reduce the adverse effects of FOLFOX4 regimen.
Collapse
Affiliation(s)
- Qi Shi
- Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China
| | - Wen Li
- Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China
| | - Qi-Qi Le
- Department of Digestive, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine University, Shanghai, 200071, China
| | - Wen-Ting Chen
- Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China
| | - Jian-Lin Ren
- Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China
| | - Qi Li
- Department of Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China
| | - Feng-Gang Hou
- Department of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, China.
| |
Collapse
|
22
|
Alleviating gastro-intestinal symptoms and concerns by integrating patient-tailored complementary medicine in supportive cancer care. Clin Nutr 2015; 34:1215-23. [DOI: 10.1016/j.clnu.2014.12.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2014] [Revised: 12/14/2014] [Accepted: 12/16/2014] [Indexed: 01/04/2023]
|
23
|
Xie X, Zhu H, Yang H, Huang W, Wu Y, Wang Y, Luo Y, Wang D, Shao G. Solamargine triggers hepatoma cell death through apoptosis. Oncol Lett 2015; 10:168-174. [PMID: 26170994 DOI: 10.3892/ol.2015.3194] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2014] [Accepted: 03/13/2015] [Indexed: 11/06/2022] Open
Abstract
Solamargine (SM), a steroidal alkaloid glycoside extracted from the traditional Chinese herb Solanum incanum, has been evidenced to inhibit the growth and induce apoptosis in a number of human cancer cell lines. In the present study, the anticancer effect of SM and underlying molecular mechanism of SM-induced apoptosis were investigated on the human hepatocellular carcinoma cells, SMMC7721 and HepG2. The proliferation effects of SM on the SMMC7721 and HepG2 cell lines were evaluated using MTT and colony formation assays. In addition, the percentage of apoptosis was measured using an Annexin V/propidium iodide staining method and the cell cycle distribution mediated by SM was analyzed using flow cytometry. The expression levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3, caspase-9, proliferating cell nuclear antigen (pcna) and Ki67 proteins were examined to further demonstrate the proliferate and apoptosis effects of SM on the hepatoma cells. The results indicated that SM effectively inhibited hepatoma cell proliferation and promoted apoptosis. SM resulted in cell cycle arrest at the G2/M phase in the two cell lines. In addition, SM downregulated the levels of proliferation-associated (Ki67 and pcna) and anti-apoptotic (Bcl-2) proteins, and promoted the activity of apoptosis-associated proteins (Bax, caspase-3 and caspase-9). Therefore, the activation of the Bcl-2/Bax and caspase signaling pathways may be involved in the SM-induced apoptosis of hepatoma cells.
Collapse
Affiliation(s)
- Xiaodong Xie
- Department of Radiology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
| | - Haitao Zhu
- Department of Radiology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
| | - Huijian Yang
- Department of Immunology, Center of Clinical Medicine and Laboratory, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China
| | - Wensi Huang
- Department of Radiology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
| | - Yingying Wu
- Department of Radiology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
| | - Ying Wang
- Department of Radiology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
| | - Yanling Luo
- Department of Radiology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
| | - Dongqing Wang
- Department of Radiology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
| | - Genbao Shao
- Department of Biology, School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China
| |
Collapse
|
24
|
Choi MJ, Kim SC, Cho SH. Intravenous injection of saeng maek san - a safe method of treatment in rats. J Pharmacopuncture 2015; 17:67-72. [PMID: 25780701 PMCID: PMC4331997 DOI: 10.3831/kpi.2014.17.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Accepted: 06/18/2014] [Indexed: 11/24/2022] Open
Abstract
Objectives: This study evaluated the single-dose toxicity of Saeng Maek San (SMS) in rats. Methods: All experiments were conducted at Biotoxtech (Chungwon, Korea), an institute authorized to perform non-clinical studies under the regulations of Good Laboratory Practice (GLP). A single-dose intravenous toxicity study was carried out on 40 6-week-old Sprague-Daley rats. The animals were randomly divided into the following four groups of ten animals each: Group 1 (G1) was the control group, with each animal receiving an intravenous injection of 1.0 mL of saline, and Groups 2, 3 and 4 (G2, G3 and G4) were the experimental groups, with the animals in the groups receiving an injection of 0.1, 0.5 and 1.0 mL of SMS, respectively. Mortality, clinical signs, body-weight changes and gross pathological findings were observed for 14 days following a single administration of SMS or saline. Organ weights, clinical chemistry and hematology were analyzed at 14 days. This study was conducted with the approval of the Institutional Animal Ethics Committee. Results: No deaths occurred in any of the four groups,indicating that the lethal dose of SMS in rats is greater than 1.0 mL/animal. Some changes in weights of male rats between the control group and the experimental groups were observed, but no significant changes in the weights of female rats were noted. To identify abnormalities in organs and tissues, we stained representative sections of each specified organ with hematoxylin and eosin for examination with a light microscope. No significant abnormalities were observed in any of the organs or tissues. Conclusion: The results suggest that intravenous injection of SMS is a safe method of treatment.
Collapse
Affiliation(s)
- Min-Ji Choi
- Department of Neuropsychiatry, College of Korean Medicine, Kyung Hee University, Seoul, Korea
| | - Sung-Chul Kim
- Department of Acupuncture & Moxibustion Medicine, Wonkwang Gwangju Oriental Medical Hospital, Gwangju, Korea
| | - Seung-Hun Cho
- Department of Neuropsychiatry, College of Korean Medicine, Kyung Hee University, Seoul, Korea ; Department of Neuropsychiatry, Hospital of Korean Medicine, Kyung Hee University Medical Center, Seoul, Korea
| |
Collapse
|
25
|
Chinese herbal medicine for myelosuppression induced by chemotherapy or radiotherapy: a systematic review of randomized controlled trials. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2015; 2015:690976. [PMID: 25802542 PMCID: PMC4352943 DOI: 10.1155/2015/690976] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Accepted: 01/21/2015] [Indexed: 11/17/2022]
Abstract
Background. Myelosuppression is one of the major side effects of chemo- and radiotherapy in cancer patients and there are no effective interventions to prevent it currently. Chinese herbal medicine (CHM) may be helpful due to its multidrug targets. Objectives. This study was designed to evaluate effectiveness of CHM on preventing patients from experiencing myelosuppression by chemo- or radiotherapy. Search Methods. Randomized controlled trials (RCTs) were retrieved from seven different databases from the date of database creation to April 2014. We assessed all included studies using Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 and performed statistical analysis using RevMan 5.2.1. Results. Eight RCTs were included (818 patients). Pooled data showed that increase of white blood cells (WBCs) is higher with CHM plus chemotherapy/radiotherapy than with chemotherapy/radiotherapy only. Both CHM compared to placebo and CHM combined with chemotherapy/radiotherapy compared to chemotherapy/radiotherapy lacked significant differences in the peripheral platelets, red blood cells (RBCs), and hemoglobin changes. Conclusions. Our results demonstrated that CHM significantly protected peripheral blood WBCs from a decrease caused by chemotherapy or radiotherapy. There were no significant protective effects on peripheral RBCs, hemoglobin, or platelets, which may be related to low quality and small sample of included studies.
Collapse
|
26
|
Guo WQ, Li LZ, He ZY, Zhang Q, Liu J, Hu CY, Qin FJ, Wang TY. Anti-proliferative effects of Atractylis lancea (Thunb.) DC. via down-regulation of the c-myc/hTERT/telomerase pathway in Hep-G2 cells. Asian Pac J Cancer Prev 2015; 14:6363-7. [PMID: 24377533 DOI: 10.7314/apjcp.2013.14.11.6363] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Atractylis lancea (Thunb.) DC. (AL), an important medicinal herb in Asia, has been shown to have anti-tumor effects on cancer cells, but the involved mechanisms are poorly understood. This study focused on potential effects and molecular mechanisms of AL on the proliferation of the Hep-G2 liver cancer cell line in vitro. Cell viability was assessed by MTT test in Hep-G2 cells incubated with an ethanol extract of AL. Then, the effects of AL on apoptosis and cell cycle progression were determined by flow cytometry. Telomeric repeat amplification protocol (TRAP) assays was performed to investigate telomerase activity. The mRNA and protein expression of human telomerase reverse transcriptase (hTERT) and c-myc were determined by real-time RT-PCR and Western blotting. Our results show that AL effectively inhibits proliferation in Hep-G2 cells in a concentration- and time-dependent manner. When Hep-G2 cells were treated with AL after 48h,the IC50 was about 72.1 μg/ mL. Apoptosis was induced by AL via arresting the cells in the G1 phase. Furthermore, AL effectively reduced telomerase activity through inhibition of mRNA and protein expression of hTERT and c-myc. Hence, these data demonstrate that AL exerts anti-proliferative effects in Hep-G2 cells via down-regulation of the c-myc/hTERT/ telomerase pathway.
Collapse
Affiliation(s)
- Wei-Qiang Guo
- School of Chemistry, Biology and Material Engineering, Suzhou University of Science and Technology, Suzhou, Jiang Su Province, China E-mail :
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Wang JW, Yang ZQ, Liu C, Chen SJ, Shen Q, Zhang TR, Partike NS, Yuan ZP, Yu JM. Cancer survivors' perspectives and experience on western medicine and traditional Chinese medicine treatment and rehabilitation: a qualitative study. Patient Prefer Adherence 2015; 9:9-16. [PMID: 25565779 PMCID: PMC4274133 DOI: 10.2147/ppa.s76617] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND In the People's Republic of China, both western medicine (WM) and traditional Chinese medicine (TCM) are the main treatment and rehabilitation options for cancer patients. This study aimed to explore cancer survivors' perspectives and experience of treatment and rehabilitation, in order to promote patient-centered activities of treatment and rehabilitation. METHODS Using a qualitative research approach, 68 cancer survivors were recruited from eight community cancer rehabilitation organizations in Shanghai, People's Republic of China. Eight focus group interviews were conducted. All these interviews were transcribed verbatim, and the data were analyzed by theme analysis. RESULTS WM was the main choice in treatment phase though study participants noted more side effects. TCM was primarily used in the recovery phase. The lack of communication between doctors and cancer patients appears to affect treatment adherence and impair the doctor-patient relationship. WM was expensive for diagnostic procedures and treatment, while the cumulative costs of frequent use of TCM in the long rehabilitation period were also high. Both treatment options created significant perceived economic burden on patients. Conflicting information about dietary supplements tended to make cancer survivors confused. CONCLUSION Improving the communication between doctors and cancer patients helps to ameliorate cancer patient adherence and the effect of treatments. It is essential to educate cancer patients about the effect and cost of both WM and traditional TCM. Meanwhile, marketing management and guidance to consumers regarding use of dietary supplements in the cancer rehabilitation field are also necessary.
Collapse
Affiliation(s)
- Ji-Wei Wang
- School of Public Health, Key Laboratory of Public Health Safety, Fudan University, Shanghai, People’s Republic of China
| | - Zhi-Qi Yang
- School of Public Health, Key Laboratory of Public Health Safety, Fudan University, Shanghai, People’s Republic of China
| | - Cong Liu
- School of Public Health, Key Laboratory of Public Health Safety, Fudan University, Shanghai, People’s Republic of China
| | - Si-Jia Chen
- School of Public Health, Key Laboratory of Public Health Safety, Fudan University, Shanghai, People’s Republic of China
| | - Qian Shen
- School of Public Health, Key Laboratory of Public Health Safety, Fudan University, Shanghai, People’s Republic of China
| | - Tian-Rui Zhang
- School of Public Health, Key Laboratory of Public Health Safety, Fudan University, Shanghai, People’s Republic of China
| | - Nancy S Partike
- School of Public Health, University of Hawaii at Manoa, Honolulu, HI, USA
| | - Zheng-Ping Yuan
- Shanghai Cancer Rehabilitation Club, Shanghai, People’s Republic of China
| | - Jin-Ming Yu
- School of Public Health, Key Laboratory of Public Health Safety, Fudan University, Shanghai, People’s Republic of China
- Correspondence: Jin-Ming Yu, School of Public Health, Key Laboratory of Public Health Safety, Fudan University, 130 Dong-An Road, Shanghai 200032, People’s Republic of China, Tel +86 21 5423 7868, Email
| |
Collapse
|
28
|
Li TF, Lin CC, Tsai HP, Hsu CH, Fu SL. Effects of Kuan-Sin-Yin decoction on immunomodulation and tumorigenesis in mouse tumor models. Altern Ther Health Med 2014; 14:488. [PMID: 25510204 PMCID: PMC4301833 DOI: 10.1186/1472-6882-14-488] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2014] [Accepted: 12/11/2014] [Indexed: 11/10/2022]
Abstract
Background Complementary therapies are widely used among cancer patients. Kuan-Sin-Yin (KSY) decoction, a popular qi-promoting herbal medicine, was constituted with several herbs known to exhibit immunomodulating or anticancer activity. After combining these herbs as a compound formula, it is necessary to reassess the immunomodulation effects, the effects on tumor growth, and possible toxicity of KSY. Methods The anti-cancer effects of KSY in vivo were determined by measuring the tumor volumes, anticancer-associated cytokines (IFN-gamma, TNF-alpha, IL-2, and IL-12), accumulation of tumor infiltrating leukocytes (TILs), proliferation and apoptosis-related molecular markers (Ki-67, p53, p21, activated caspase 3, and cleaved PARP), and an in situ TUNEL assay. The body weight and serum chemistry of treated mice were also assessed. In vitro, the effects of KSY were evaluated using MTT assay, BrdU incorporation assay and cell growth curve. Results In vivo, KSY suppressed bladder or lung cancer growth but did not promote the production of cytokines nor increase the accumulation of TILs. The expression of p53 and p21 in KSY-treated mice were increased. The numbers of apoptotic tumor cells and the expression of apoptosis marker proteins (Caspase 3 and cleaved PARP) were not significantly elevated after KSY treatment. In vitro, the viability and proliferation of tumor cells, but not normal cells, were suppressed by KSY treatment. No significant toxicity was found in KSY-treated mice. Conclusions KSY suppressed the tumor growth in vivo and in vitro, which resulted from its cytostatic effects on cancer cells, rather than the induction of anti-cancer immunity. Under these experimental conditions, no apparent toxicity was observed. Electronic supplementary material The online version of this article (doi:10.1186/1472-6882-14-488) contains supplementary material, which is available to authorized users.
Collapse
|
29
|
Hong W, Dong E. The past, present and future of breast cancer research in China. Cancer Lett 2014; 351:1-5. [PMID: 24735750 DOI: 10.1016/j.canlet.2014.04.007] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Revised: 03/31/2014] [Accepted: 04/07/2014] [Indexed: 10/25/2022]
Abstract
The incidence of breast cancer has increased rapidly in recent years and has now become the most common cancer in women in major cities of China. Here, we reviewed the history and progress of breast cancer research in China, including achievements that Chinese scientists have made in basic, translational and clinical research. Moreover, we evaluated the contributions of National Natural Science Foundation of China (NSFC) in the field of breast cancer research. The number of grants funded by the NSFC for breast cancer has tripled from 87 to 274 in the past 5years, and this resulted in a dramatic increase in breast cancer publications. Despite this great progress, policy makers are continuously taking efforts to guarantee the transparency of grant competition and the effective use of NSFC finding.
Collapse
Affiliation(s)
- Wei Hong
- Department of Health Sciences, National Natural Science Foundation of China, Beijing, China
| | - Erdan Dong
- Department of Health Sciences, National Natural Science Foundation of China, Beijing, China.
| |
Collapse
|
30
|
Liu CH, Tang WR, Wang HM, Lee KC. How cancer patients build trust in traditional Chinese medicine. Eur J Integr Med 2013. [DOI: 10.1016/j.eujim.2013.08.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
31
|
Schröder S, Lee S, Efferth T, Motoo Y. Acupuncture and herbal medicine for cancer patients. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE : ECAM 2013; 2013:313751. [PMID: 24371455 PMCID: PMC3858869 DOI: 10.1155/2013/313751] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/27/2013] [Accepted: 10/27/2013] [Indexed: 11/17/2022]
Affiliation(s)
- S. Schröder
- HanseMerkur Center for Traditional Chinese Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
| | - S. Lee
- Department of Clinical Oncology, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - T. Efferth
- Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, StaudingerWeg 5, 55128 Mainz, Germany
| | - Y. Motoo
- Department of Medical Oncology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan
| |
Collapse
|
32
|
Arslan D, Tural D, Akar E. Herbal Administration and Interaction of Cancer Treatment. J Palliat Med 2013; 16:1466-76. [DOI: 10.1089/jpm.2013.0126] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Deniz Arslan
- Department of Medical Oncology, Akdeniz University, Antalya, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Istanbul University, Istanbul, Turkey
| | - Emre Akar
- Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey
| |
Collapse
|
33
|
Therapeutic applications of herbal medicines for cancer patients. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2013; 2013:302426. [PMID: 23956768 PMCID: PMC3727181 DOI: 10.1155/2013/302426] [Citation(s) in RCA: 166] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/30/2013] [Revised: 06/17/2013] [Accepted: 06/19/2013] [Indexed: 12/12/2022]
Abstract
Medicinal herbs and their derivative phytocompounds are being increasingly recognized as useful complementary treatments for cancer. A large volume of clinical studies have reported the beneficial effects of herbal medicines on the survival, immune modulation, and quality of life (QOL) of cancer patients, when these herbal medicines are used in combination with conventional therapeutics. Here, we briefly review some examples of clinical studies that investigated the use of herbal medicines for various cancers and the development of randomized controlled trials (RCTs) in this emerging research area. In addition, we also report recent studies on the biochemical and cellular mechanisms of herbal medicines in specific tumor microenvironments and the potential application of specific phytochemicals in cell-based cancer vaccine systems. This review should provide useful technological support for evidence-based application of herbal medicines in cancer therapy.
Collapse
|
34
|
Berkovitz S, Bassett P, Hughes J. A randomised double-blind comparability study of a placebo for Individualised Western Herbal Medicine. Complement Ther Med 2013; 21:195-9. [DOI: 10.1016/j.ctim.2013.03.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2012] [Revised: 02/08/2013] [Accepted: 03/11/2013] [Indexed: 01/13/2023] Open
|
35
|
Deng W, Sui H, Wang Q, He N, Duan C, Han L, Li Q, Lu M, Lv S. A Chinese herbal formula, Yi-Qi-Fu-Sheng, inhibits migration/invasion of colorectal cancer by down-regulating MMP-2/9 via inhibiting the activation of ERK/MAPK signaling pathways. Altern Ther Health Med 2013; 13:65. [PMID: 23506655 PMCID: PMC3617034 DOI: 10.1186/1472-6882-13-65] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2012] [Accepted: 03/11/2013] [Indexed: 02/07/2023]
Abstract
Background A Chinese herbal formula, Yi-Qi-Fu-Sheng (YQFS), has long been employed clinically to treat cancer patients. We aimed to determine its effectiveness as a treatment method for colorectal cancer. We investigated the therapeutic effects of YQFS on colorectal cancer, as well as the underlying mechanisms, which have not previously been explored. Methods First, YQFS was extracted and chemically characterized. We then tested the effects of YQFS on proliferation and migration by MTT and transwell migration assays in vitro. Mouse xenograft models of colorectal cancer were established by inoculation with HCT-116 cells, and mice received one of three oral doses (200, 400 and 800 mg/kg/day) to evaluate the effects of YQFS extract. Metalloproteinase-2/9 (MMP-2/9) expression in mice was evaluated by gelatin zymography assay. Apoptosis was evaluated by flow cytometry (FCM) analysis in vitro and by TUNEL assay in vivo. ERK and p-ERK expression were evaluated by western blot analysis at the protein level in vitro, and by quantitative RT-PCR at mRNA level in vivo. Results Our results show that YQFS significantly inhibits colorectal cancer cell proliferation and induces apoptosis and cell cycle arrest at the G1− and S-phase in HCT-116 cells. Furthermore, YQFS effectively retards tumor cell migration and invasion by inhibiting metalloproteinase-2/9 (MMP-2/9) expression, both in vitro and in vivo. Moreover, YQFS had an inhibitory effect on tumor growth in vivo, and induced apoptosis through the inhibition of the ERK1/2 pathway both in vitro and in vivo. Conclusion These findings demonstrate that YQFS extract has an anti-tumor effect in colorectal cancer, which could be attributed to ERK1/2-dependent inhibition of MMP-2/9 expression.
Collapse
|
36
|
Lo LC, Chen CY, Chen ST, Chen HC, Lee TC, Chang CS. Therapeutic efficacy of traditional Chinese medicine, Shen-Mai San, in cancer patients undergoing chemotherapy or radiotherapy: study protocol for a randomized, double-blind, placebo-controlled trial. Trials 2012. [PMID: 23206440 PMCID: PMC3543266 DOI: 10.1186/1745-6215-13-232] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Background Cancer is one of the major health issues worldwide. An increasing number of cancer patients are offered treatment with surgery, chemotherapy and radiotherapy. Traditional Chinese medicine (TCM) is one of the most common complementary therapies offered to cancer patients in Taiwan. We designed a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of TCM in patients with cancer. Methods/design In this study, inclusion criteria are postoperative patients with histologically confirmed cancer within 3 years who are undergoing chemotherapy or radiotherapy, more than 18 years old, have given signed informed consent, have the ability to read Chinese, and the ability for oral intake. Exclusion criteria include being pregnant, breast feeding, having completed chemotherapy or radiotherapy, brain metastasis with Eastern Cooperative Oncology Group (ECOG) performance status of two to four, delusion or hallucinations, acute infection, and have received medications under other clinical trials. The patients were separated into an intervention group (Shen-Mai-San, SMS) and a placebo group for four weeks using a randomized, double-blind procedure. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QOL-C30) was used to evaluate the quality of life. General data, hemoglobin (Hb), hematocrit (Hct), glutamic-oxalacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), blood urea nitrogen (BUN), creatinine, carcinoembryonic antigen (CEA), TCM diagnosis data and heart rate variability (HRV) were also recorded. These data were collected at baseline, two weeks and four weeks after receiving medication. The patients were prescribed granules which contained therapeutic medicines or placebo. Paired-T test was used for statistical analysis. Discussion Shen-Mai-San is composed of processed Ginseng radis, Liriope spicata, and Schizandrae fructus. It was found to be effective for treating cancer-related fatigue and had anti-fatigue activity. In TCM theory, SMS has a synergistic effect for qi and yin deficiency and has the ability to prevent fatigue. The symptoms of qi and yin deficiency are similar to chemotherapy- or radiotherapy-induced side effects. In order to evaluate the efficacy of SMS on cancer treatment, we designed a randomized, double-blind, placebo-controlled trial. Trial registration This study is registered to Clinical Trails.gov NCT01580358
Collapse
Affiliation(s)
- Lun-Chien Lo
- Department of Chinese Medicine, Changhua Christian Hospital, 135 NanxiaoSt, Changhua City, Changhua Country 500, Taiwan
| | | | | | | | | | | |
Collapse
|
37
|
Xu L, Li H, Xu Z, Wang Z, Liu L, Tian J, Sun J, Zhou L, Yao Y, Jiao L, Su W, Guo H, Chen P, Liu J. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients. Altern Ther Health Med 2012; 12:112. [PMID: 22853619 PMCID: PMC3502343 DOI: 10.1186/1472-6882-12-112] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2012] [Accepted: 07/18/2012] [Indexed: 11/10/2022]
Abstract
Background Traditional Chinese medicine (TCM) is a widely applied complementary therapy for cancer patients. It can reduce the chemical drugs induced toxic effects to improve the quality of life (QOL). This study applies the highest quality of clinical trial methodology to examine the role of TCM in improving QOL of postoperative non-small-cell lung cancer patients. Methods and design This study is a multi-center, randomized, placebo-controlled, double-blind trial. Four hundred eighty patients will be recruited into seven different research centers in China. These patients that meet the inclusion criteria will be randomized into either a treatment group or a placebo group. Each group will receive treatments of 3-weekly chemotherapy with TCM or placebo for four cycles. The primary outcome will involve the evaluation of QOL and the secondary outcome assessments will include two-year disease-free survival rate and disease-free survival. Other efficacy assessments are changes of TCM symptoms and toxicity. Side effects and safety profile of the therapy would be evaluated at the same time. The investigators expect that TCM therapy combined with chemotherapy is superior to chemotherapy solely in terms of QOL improvement and disease-free survival extension. "Intention-to-treat" analysis will include all randomized participants. Discussion The results from the clinical trial will provide evidence for the effectiveness of chemotherapy combined with or without TCM in QOL of postoperative NSCLC patients. Trial registration Clinical Trials.gov (Identifier: NCT01441752).
Collapse
|
38
|
Safety and Efficacy of Tien-Hsien Liquid Practical in Patients with Refractory Metastatic Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IIa Trial. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2012; 2012:803239. [PMID: 22548120 PMCID: PMC3321543 DOI: 10.1155/2012/803239] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/15/2011] [Accepted: 01/18/2012] [Indexed: 12/12/2022]
Abstract
To evaluate the safety and efficacy of Tien-Hsien Liquid Practical (THL-P), a Chinese herbal mixture, in patients with refractory metastatic breast cancer, we performed a randomized, double-blind, placebo-controlled, parallel-group, phase IIa pilot trial. Patients were randomly assigned to either receive THL-P or matching placebo and followed up every 4 weeks for 24 weeks. The primary endpoint was changes in the global health status/quality of life (GHS/QOL) scale. The secondary endpoints were changes in functional and symptom scales, immunomodulating effects, and adverse events. Sixty-three patients were enrolled between June 2009 and June 2011. The intent-to-treat population included 28 patients in the THL-P group and 11 patients in the placebo group. Compared to the placebo group, the THL-P group had significant improvement from baseline to last visit in GHS/QOL (41.7 versus −33.3; P < 0.05), CD3, CD4/CD8, CD19, CD16+56 positive cells (P < 0.05), and higher levels of physical, role, emotional, and cognitive functioning, as well as decreased fatigue and systemic side effects. Treatment-related adverse events were mild constipation and localized itching, and no serious adverse events were reported. THL-P appears to be a safe alternative adjuvant treatment for patients with refractory metastatic breast cancer, as it effectively improves QOL and palliates cancer-related symptoms.
Collapse
|
39
|
Cancer patients' experience of combined treatment with conventional and traditional Chinese medicine: a biopsychosocial phenomenon. Cancer Nurs 2012; 34:495-502. [PMID: 21372696 DOI: 10.1097/ncc.0b013e31820d4da9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Traditional Chinese medicine (TCM) is used worldwide as a complementary and alternative medicine, but little is known about cancer patients' experience when using combination therapy of TCM and conventional medicine. OBJECTIVES The goal of this study was to understand the experiences of Taiwanese cancer patients undergoing conventional chemotherapy and using TCM at the same time. METHODS For this qualitative descriptive study, 9 cancer patients (42-63 years old) were interviewed individually and in depth using a semistructured guide. All interviews were audiotaped and transcribed verbatim. Data were concurrently collected and analyzed using a constant comparative method to develop major themes and categories. RESULTS Data analysis revealed 3 themes: (1) biomedical aspect: TCM as a supplementary force to conventional medicine, (2) psychological aspect: different beliefs about TCM create different TCM uses, and (3) social aspect: interactions among patients, physicians, and economic issues. CONCLUSIONS Our study reveals that the phenomenon of using TCM is captured in a biopsychosocial model. IMPLICATIONS FOR PRACTICE When assessing the issue of TCM use among cancer patients, healthcare providers must take into consideration its biological, psychological, and social aspects.
Collapse
|
40
|
McCulloch M, Broffman M, van der Laan M, Hubbard A, Kushi L, Abrams DI, Gao J, Colford JM. Colon cancer survival with herbal medicine and vitamins combined with standard therapy in a whole-systems approach: ten-year follow-up data analyzed with marginal structural models and propensity score methods. Integr Cancer Ther 2011; 10:240-59. [PMID: 21964510 DOI: 10.1177/1534735411406539] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Although localized colon cancer is often successfully treated with surgery, advanced disease requires aggressive systemic therapy that has lower effectiveness. Approximately 30% to 75% of patients with colon cancer use complementary and alternative medicine (CAM), but there is limited formal evidence of survival efficacy. In a consecutive case series with 10-year follow-up of all colon cancer patients (n = 193) presenting at a San Francisco Bay-Area center for Chinese medicine (Pine Street Clinic, San Anselmo, CA), the authors compared survival in patients choosing short-term treatment lasting the duration of chemotherapy/radiotherapy with those continuing long-term. To put these data into the context of treatment responses seen in conventional medical practice, they also compared survival with Pan-Asian medicine + vitamins (PAM+V) with that of concurrent external controls from Kaiser Permanente Northern California and California Cancer Registries. Kaplan-Meier, traditional Cox regression, and more modern methods were used for causal inference-namely, propensity score and marginal structural models (MSMs), which have not been used before in studies of cancer survival and Chinese herbal medicine. PAM+V combined with conventional therapy, compared with conventional therapy alone, reduced the risk of death in stage I by 95%, stage II by 64%, stage III by 29%, and stage IV by 75%. There was no significant difference between short-term and long-term PAM+V. Combining PAM+V with conventional therapy improved survival, compared with conventional therapy alone, suggesting that prospective trials combining PAM+V with conventional therapy are justified.
Collapse
|
41
|
Abstract
Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes involving ALK has set the stage for personalized medicine for lung cancer. Patients selected using biomarkers have benefited from the development of EGFR tyrosine kinase inhibitors and ALK inhibitors with considerable improvement in tumor control and survival. Four key areas of knowledge that are essential to the development of targeted therapy are discussed in this Review: knowing the target, knowing the biomarker, knowing the end point and knowing the mechanisms of resistance.
Collapse
Affiliation(s)
- Tony S K Mok
- Department of Clinical Oncology, The Chinese University of Hong Kong, State Key Laboratory of South China, Sha Tin, Hong Kong, China.
| |
Collapse
|
42
|
Yaal-Hahoshen N, Maimon Y, Siegelmann-Danieli N, Lev-Ari S, Ron IG, Sperber F, Samuels N, Shoham J, Merimsky O. A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer. Oncologist 2011; 16:1197-202. [PMID: 21712486 DOI: 10.1634/theoncologist.2011-0150] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND This prospective, controlled study evaluated the safety, tolerability, and efficacy of the mixture of botanical compounds known as LCS101 in preventing chemotherapy-induced hematological toxicity in breast cancer patients. METHODS Female patients diagnosed with localized breast cancer were randomly allocated to receive treatment with either LCS101 or placebo capsules, in addition to conventional chemotherapy. The study intervention was initiated 2 weeks prior to the initiation of chemotherapy and continued until chemotherapy was completed, with participants receiving 2 g of LCS101 capsules thrice daily. Subjects were assessed for the development of hematological and nonhematological toxicities, as well as the tolerability and safety of the study intervention. RESULTS Sixty-five breast cancer patients were recruited, with 34 allocated to LCS101 and 31 allocated to placebo treatment. Patients in the treatment group developed significantly less severe (grades 2-4) anemia (p < .01) and leukopenia (p < .03) when comparing grades 0-1 with grades 2-4, with significantly less neutropenia (p < .04) when comparing grades 0-2 with grades 3-4. This effect was more significant among patients undergoing a dose-dense regimen. No statistically significant effect was found with respect to nonhematological toxicities, and side effect rates were not significantly different between the groups, with no severe or life-threatening events observed in either group. CONCLUSION The addition of LCS101 to anthracycline- and taxane-based chemotherapy is safe and well tolerated, and may significantly prevent some chemotherapy-induced hematological toxicities in early breast cancer patients. These results should encourage further larger and more extensive clinical trials.
Collapse
Affiliation(s)
- Neora Yaal-Hahoshen
- Refuot Integrative Medical Center, 18 Feinstein Street, Tel Aviv 69123, Israel
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Chan KKL, Yao TJ, Jones B, Zhao JF, Ma FK, Leung CY, Lau SK, Yip MW, Ngan HYS. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol 2011; 22:2241-9. [PMID: 21355071 DOI: 10.1093/annonc/mdq749] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND This study aimed to evaluate traditional Chinese medicine (TCM) in improving quality of life (QOL), reducing chemotoxicity and modulating immune function in patients undergoing chemotherapy. PATIENTS AND METHODS Patients with ovarian cancer were randomized to receive either TCM or placebo in addition to standard chemotherapy. The primary outcome was global health status (GHS) score, assessed by European Organization for Research and Treatment of Cancer questionnaire, while the secondary outcomes were other QOL items, chemotoxicity according to World Health Organization criteria and alterations in immune function as measured by immune cells count and the numbers of cytokines-secreting cells. RESULTS There was no significant difference in the GHS between the two groups. With adjustment for stage, chemotherapy type, disease status, age and baseline value, emotional function, cognitive function and nausea and vomiting were found to be worse or less improved in the TCM group compared with placebo group after six cycles of chemotherapy. The TCM group had less neutropenia after three cycles (0% grade 4 neutropenia versus 28.6%). There were no other significant differences in terms of chemotoxicity. Lymphocyte counts and cytokine activities decreased less in the TCM group. CONCLUSIONS TCM did not improve QOL but did have some effects in terms of maintaining immune function.
Collapse
Affiliation(s)
- K K L Chan
- Department of Obstetrics and Gynaecology, Queen Mary Hospital, Hong Kong.
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
He SM, Yang AK, Li XT, Du YM, Zhou SF. Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol 2010; 6:1195-213. [PMID: 20701553 DOI: 10.1517/17425255.2010.510132] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
IMPORTANCE OF THE FIELD Cancer patients on chemotherapy treatment often seek herbal therapies and this may alter the clearance of anticancer drugs. AREAS COVERED IN THIS REVIEW Many anticancer drugs are metabolized by CYPs and are substrates of P-glycoprotein, breast cancer resistance protein and multi-drug resistance proteins. CYPs and drug transporters are subject to inhibition and/or induction by the herbal medicines used by cancer patients and the metabolism and pharmacokinetics of anticancer agents may be altered by herbal products. There are increased reports on the interaction of herbal medicines with anticancer agents. A clinical study in cancer patients reported that treatment of St John's wort at 900 mg/day orally for 18 days decreased the plasma levels of the active metabolite of irinotecan, SN-38, by 42%. In healthy subjects, treatment with St John's wort for 2 weeks significantly decreased the systemic exposure of imatinib by 32%. Induction and/or inhibition of CYPs and transporters is considered an important mechanism for these interactions. WHAT THE READER WILL GAIN Potential interactions of herbal medicines with anticancer agents have become a safety concern in cancer chemotherapy. TAKE HOME MESSAGE Further studies are warranted to investigate the efficacy and safety profiles of herbal medicines commonly used by cancer patients.
Collapse
Affiliation(s)
- Shu-Ming He
- Xiaolan People's Hospital Affiliated to Nanfang Medical University, Department of Obstetrics and Gynecology, Zhongshan, Guangdong, China
| | | | | | | | | |
Collapse
|
45
|
Evidence-Based Management of Herb-Drug Interaction in Cancer Chemotherapy. Explore (NY) 2010; 6:324-9. [DOI: 10.1016/j.explore.2010.06.004] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2009] [Indexed: 12/11/2022]
|
46
|
Molassiotis A, Potrata B, Cheng K. A systematic review of the effectiveness of Chinese herbal medication in symptom management and improvement of quality of life in adult cancer patients. Complement Ther Med 2009; 17:92-120. [DOI: 10.1016/j.ctim.2008.11.002] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2008] [Revised: 10/15/2008] [Accepted: 11/03/2008] [Indexed: 11/24/2022] Open
|
47
|
|
48
|
Complications of traditional Chinese/herbal medicines (TCM)--a guide for perplexed oncologists and other cancer caregivers. Support Care Cancer 2008; 17:231-40. [PMID: 19009311 DOI: 10.1007/s00520-008-0526-x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2008] [Accepted: 10/13/2008] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Cancer patients often seek complementary or alternative medicines to supplement or replace treatments prescribed by licensed medical practitioners. Traditional Chinese/herbal medicine (TCM) is a popular complementary intervention among cancer patients of Asian ethnicity, many of whom take it during their conventional treatment. Few of these patients inform their doctors, however, creating a risk of unexpected sequelae arising from either pharmacologic toxicity, unsuitable dosing, interactions with anti-cancer drugs or other medications, adulteration, or idiosyncratic reactions. If unrecognized, these problems may be misattributed to conventional treatment toxicity or disease progression, and remedial action may be inappropriate or delayed. GOALS OF WORK The purpose of this review is to help oncologists recognize the common presentations of TCM-related problems in cancer patients-such as abnormal liver function tests, unexpectedly severe myelosuppression, hemostatic defects, renal functional impairment, or suspected drug interactions-and to teach strategies by which these problems can be anticipated, prevented, or managed. CONCLUSION Through sensitive understanding of the reasons favoring TCM usage, oncologists can gain the trust and respect of their TCM-using patients while ensuring the safety and efficacy of conventional anticancer treatments.
Collapse
|
49
|
|
50
|
|